FDA Questions Genasense's Efficacy Prior To ODAC Panel

FDA examining guidance for emergency research

FDA Questions Genasense's Efficacy Prior To ODAC Panel

Auxilium, Oscient End Testim Pact; Auxilium Signing Lease

Invitrogen Unveils Merger Plan For Sentigen: $25.9M In Cash

FDA Examining Guidance For Emergency Research

FDA Examining Guidance For Emergency Research

Invitrogen Unveils Merger Plan For Sentigen: $25.9M In Cash

Cerus Settles Class-Action Suit, Ends Headache For Management

Cerus Settles Class-Action Suit, Ends Headache For Management